It suggests that type 2 mellitus and AD, in particular sporadic AD (sAD), share common risk factors, and molecular mechanisms, including impairment of insulin/IGF—1 signaling, and thus potentially common therapeutic targets [15]. This evidence concerns the gene INS and Alzheimer disease.